Nationally Notifiable Infectious Diseases and Conditions, United States: Annual Tables

TABLE 2g. Annual reported cases* of notifiable diseases, by region and reporting area, United States, U.S. Territories, and Non-U.S. Residents, 2020†
Data from some reporting areas may be incomplete due to the coronavirus disease 2019 (COVID-19) pandemic or due to post-reconciliation data updates that could not be confirmed or included in the final data set. Please see Note #9 and Note #10, respectively.
Reporting Area Giardiasis Gonorrhea Haemophilus influenzae, invasive disease Hansen's disease
All ages, all serotypes Age <5 years
Serotype b Non-b serotype Nontypeable Unknown serotype
U.S. Residents, excluding U.S. Territories 9,453 677,751 2,996 15 76 104 121 68
New England 662 14,616 131 — 1 5 — 1
Connecticut 132 4,603 30 — — — — 1
Maine 140 520 9 — — 1 — N
Massachusetts 274 7,494 55 — — 4 — —
New Hampshire 85 461 16 — 1 — — —
Rhode Island 31 1,399 12 — — — — —
Vermont N 139 9 — — — — N
Middle Atlantic 2,049 70,857 390 4 5 7 13 5
New Jersey 210 10,060 66 — — — 5 —
New York (excluding New York City) 790 17,291 113 1 — — 5 N
New York City 655 25,226 66 1 3 — — 3
Pennsylvania 394 18,280 145 2 2 7 3 2
East North Central 1,273 109,901 521 5 26 24 5 2
Illinois N 31,055 108 1 3 8 — —
Indiana 143 14,111 88 1 5 2 1 2
Michigan 375 23,412 101 1 3 3 2 —
Ohio 268 30,977 153 1 8 8 1 —
Wisconsin 487 10,346 71 1 7 3 1 —
West North Central 1,024 47,238 246 — 5 — 23 2
Iowa 149 6,919 3 — — — — 1
Kansas 106 5,626 44 — — — 6 —
Minnesota 419 10,320 59 — — — 7 —
Missouri 148 16,855 94 — — — 6 1
Nebraska 78 3,434 24 — — — 3 —
North Dakota 58 1,660 5 — 1 — — N
South Dakota 66 2,424 17 — 4 — 1 —
South Atlantic 1,373 143,645 728 1 9 13 28 27
Delaware 24 1,503 9 — — — — —
District of Columbia 23 3,879 7 — — — — —
Florida 656 40,788 207 — 1 3 15 27
Georgia 223 23,463 133 1 1 — 4 —
Maryland 94 12,052 78 — — 1 2 —
North Carolina N 28,258 138 — 4 7 1 —
South Carolina 118 16,705 49 — — — 2 —
Virginia 152 15,217 73 — 2 2 4 —
West Virginia 83 1,780 34 — 1 — — N
East South Central 131 55,033 219 2 7 14 7 3
Alabama 131 14,425 55 1 1 3 4 1
Kentucky N 8,377 38 1 2 2 1 1
Mississippi N 13,773 29 — 4 — — —
Tennessee N 18,458 97 — — 9 2 1
West South Central 254 92,790 398 1 9 20 18 6
Arkansas 88 7,857 44 — 3 4 — —
Louisiana 166 15,483 61 1 — 1 4 1
Oklahoma N 11,204 87 — 4 5 — N
Texas N 58,246 206 — 2 10 14 5
Mountain 896 43,682 260 2 6 14 6 —
Arizona 84 16,342 91 — 4 5 2 —
Colorado 337 9,686 51 — — 2 1 —
Idaho 114 1,480 17 — — 2 — —
Montana 74 1,698 13 — — — — —
Nevada 53 6,364 19 — — — — —
New Mexico 46 4,608 30 1 — 2 2 —
Utah 156 3,112 35 1 2 3 1 —
Wyoming 32 392 4 — — — — —
Pacific 1,791 99,989 103 — 8 7 21 22
Alaska 87 1,982 14 — 4 1 — —
California 1,237 78,444 20 — — — 20 7
Hawaii 27 1,484 11 — — — 1 15
Oregon 256 6,412 52 — 1 3 — N
Washington 184 11,667 6 — 3 3 — N
U.S. Territories 42 692 — — — — — 2
American Samoa — 24 — — — — — —
Commonwealth of Northern Mariana Islands — 3 — — — — — —
Guam 1 208 — — — — — 2
Puerto Rico 41 390 — — — — — —
U.S. Virgin Islands — 67 — — — — — —
Non-U.S. Residents 5 18 — — — — — —
Total 9,500 678,461 2,996 15 76 104 121 70
  • —: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
  • N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.
  • U: Unavailable — The data are unavailable.
  • * Cases are assigned to the reporting jurisdiction submitting the case to NNDSS if the case's country of usual residence is the United States, a U.S. territory, unknown, or country is not reported; otherwise, the case is assigned to the Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions because this data element is only available in the HL7 generic version 2 and disease-specific message mapping guides. If a jurisdiction sends data in legacy formats, they are not able to send this information. For further information on interpretation of these data, see https://www.cdc.gov/nndss/data-statistics/readers-guides/.
  • † To calculate rates, use the populations provided in Table 8. Note that calculation of rates for the following conditions use population subsets presented in Table 8: Zika virus infection, congenital; Zika virus disease, congenital; Infant botulism; Congenital rubella syndrome; Perinatal Hepatitis B infection; Perinatal Hepatitis C infection; Haemophilus influenzae, invasive disease; Invasive pneumococcal disease; and Influenza-associated pediatric mortality. Also see Notes #3 and #7.
Notes:
  1. These are annual cases of selected infectious national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published. Cases are reported by state health departments to CDC weekly. Because source datasets may be updated as additional information is received, statistics in publications based on that source data may differ from what is presented in these tables. Source datasets for the 2020 annual tables were officially closed on September 27, 2022.
  2. The list of national notifiable Infectious diseases and conditions for 2020 and their national surveillance case definitions are available by navigating to the Surveillance Case Definitions | CDC web page, selecting "2020" for the notifiable condition list year, checking "Infectious" conditions, and clicking "Get Notifiable List by Year". This list incorporates the Council of State and Territorial Epidemiologists (CSTE) position statements approved in 2019 by CSTE for national surveillance that were implemented in January 2020. Revised case definitions were implemented for the following conditions: plague, legionellosis, acute hepatitis C, spotted fever rickettsiosis, and pertussis. In addition, CSTE adopted the first coronavirus disease 2019 (COVID-19) national surveillance case definition on April 5, 2020, and they approved a revision to the COVID-19 national surveillance case definition, effective August 5, 2020. Publication criteria for the finalized 2020 data are available at https://wonder.cdc.gov/nndss/documents/2020_NNDSS_Publication_Criteria_03162022.pdf. See also Guide to Interpreting Provisional and Finalized NNDSS Data.
  3. Population estimates for incidence rates are July 1st, 2020, estimates obtained from the National Center for Health Statistics (NCHS) postcensal estimates of the resident population of the United States for April 1, 2010, to July 1, 2020, by year, county, single year of age (range: 0 to 85 years), bridged-race (white, black or African American, American Indian or Alaska Native, Asian, or Pacific Islander), Hispanic ethnicity (not Hispanic or Latino, Hispanic or Latino), and sex (Vintage 2020), prepared under a collaborative arrangement with the U.S. Census Bureau. Population estimates for states released September 21, 2021, are available at https://www.cdc.gov/nchs/nvss/bridged_race/data_documentation.htm. Population estimates for territories are the 2020 mid-year estimates from the U.S. Census Bureau International Data Base, accessed on March 15, 2022, at https://www.census.gov/data-tools/demo/idb/#/country?YR_ANIM=2022. The choice of population denominators for incidence is based on the availability of population data at the time of publication preparation.
  4. Annual tables for 2016 and later years are available on CDC WONDER.
  5. Annual summary reports from 1993–2015 are available as published in the Morbidity and Mortality Weekly Report.
  6. NNDSS annual tables since 1952 are available at CDC Stacks (once in CDC Stacks, select "Annual Reports" in the "Genre" box to the left).
  7. For most conditions, national incidence rates are calculated as the number of reported cases for each infectious disease or condition divided by the U.S. resident population for the specified demographic population or the total U.S. resident population, multiplied by 100,000. When a national notifiable infectious condition is associated with a specific age restriction, the same restriction was applied to the population in the denominator of the incidence rate calculation. In addition, population data from reporting jurisdictions in which the disease or condition was not reportable or not available were excluded from the denominator of the incidence rate calculations.

    Age restrictions in the numerator and denominator are applied for the following childhood conditions:

    • Zika virus disease, congenital (age restriction in numerator and denominator is <1 year)
    • Zika virus infection, congenital (age restriction in numerator and denominator is <1 year)
    • Haemophilus influenzae, invasive disease <5 years (age restriction in numerator and denominator is <5 years)
    • Invasive pneumococcal disease <5 years (age restriction in numerator and denominator is <5 years)
    • Influenza associated pediatric mortality (age restriction in numerator and denominator is <18 years)
    • Infant botulism (age restriction in numerator and denominator is <1 year)
    • Congenital rubella syndrome (age restriction in numerator and denominator is <1 year)
    • Perinatal hepatitis B infection (age restriction in numerator is ≤24 months, denominator is <24 months)
    • Perinatal hepatitis C infection (age restriction in numerator is ≤36 months, denominator is <36 months).

    Data for congenital syphilis are aggregated by the infant's year of birth. The rate for congenital syphilis is based upon the number of reported cases per 100,000 live births, using natality data for 2020 (National Center for Health Statistics Natality 2020, as compiled from data provided by the Vital Statistics Cooperative Program). Congenital syphilis cases are usually assigned to the mother's state of residence at the time of delivery. The mother's race and ethnicity are used for race- and ethnicity-specific rates of congenital syphilis cases.

  8. Surveillance data reported by other CDC programs might vary from data reported in these tables because of differences in 1) the date used to aggregate the data, 2) the timing of reports, 3) the source of the data, 4) surveillance case definitions, and 5) policies regarding case jurisdiction (i.e., which jurisdiction should submit the case notification to CDC).
  9. The following reporting areas may have incomplete data, due to technical or programmatic challenges while reconciling data during the COVID-19 pandemic: California, Guam, and Minnesota.
  10. The following reporting areas may have incomplete data due to updates made to their data after the 2020 reconciliation period ended and there was not sufficient time before publication of the annual tables to confirm the updated counts: Idaho, Kansas, Maryland, Vermont, and Virgin Islands.
  11. Of the reporting areas that submitted 2020 aggregate COVID-19 data to CDC, three did not submit probable cases. New York (excluding New York City) and Utah did not collect probable cases. U.S. Virgin Islands collected probable cases, but did not report them to CDC.
  12. Disease data presented in the 2020 tables reflect impacts of the COVID-19 pandemic, such as changes in exposure-related behavior, healthcare-seeking behavior, disease reporting, and public health investigations.
Suggested Citation: Acknowledgment:
  • CDC acknowledges the local, state, and territorial health departments that collected the data from a range of case ascertainment sources (e.g., healthcare providers, hospitals, laboratories) and reported these data to CDC's National Notifiable Diseases Surveillance System.